La chaîne d'options affiche les données clés des options sur actions de Vir Biotechnology à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Vir Biotechnology..

Vir Biotechnology (NASDAQ:VIR) Stock, Chaîne d'Options

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Virtu Financial, Inc. Class A Common Stock

Virtu Financial Inc

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Viratech Corp

Neuralbase AI Ltd

Viracta Therapeutics Inc

Press Releases

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

ArriVent BioPharma

Bicara Therapeutics

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Gyre Therapeutics

Immatics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Kura Oncology

Myriad Genetics

Nurix Therapeutics

Organogenesis Holdings

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Relay Therapeutics

Rezolute

Sana Biotechnology

Tango Therapeutics

Tourmaline Bio

Tyra Biosciences

Valneva

Verastem

Zenas BioPharma

Evercore ISI Group

B of A Securities

Raymond James

Needham

Goldman Sachs

Comments

Vir Biotechnology

Vir Biotechnology (VIR) Options

Vir Biotechnology (NASDAQ:VIR) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL